89bio, Inc.

    Jurisdiction
    United States
    ISIN
    US2825591033 (ETNB)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €18.12K
    Gross margin
    61.9%
    EBIT
    -€401.90M
    EBIT margin
    -2,217,504.8%
    Net income
    -€388.54M
    Net margin
    -2,143,838.1%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A -€328.68M -15.4%
    €27.78M -€355.40M +8.1%
    €206.97M +645.2% -€255.84M -28.0%

    Dividends

    No dividend payouts

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 504K $3.67M +207K Buy

    Add to watchlist

    Notifications